20 articles
A randomized trial found hypothermic oxygenated perfusion slashed early graft failure rates from 37% to 20% in liver transplant patients.
BioCardia's bone marrow cell therapy shows lasting gains in exercise tolerance and dramatic angina reduction in chronic heart disease patients.
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
Breakthrough therapy targeting hypoxic-ischemic encephalopathy in newborns receives significant funding, potentially becoming first HIE drug.
UC Riverside scientists developed a gel that delivers continuous oxygen to chronic wounds, healing fatal injuries in diabetic mice within weeks.
A landmark meta-analysis shows aerobic, combined, and HIIT training all significantly reduce ambulatory blood pressure — a stronger mortality predictor.
A phase 3 trial finds combining two hormone therapies before and after prostate surgery outperforms single hormone therapy in high-risk cases.
A transdermal patch delivering PAH drug treprostinil via a liver-activated prodrug shows promising Phase 1 safety and delivery results.
New research reveals 71% of chronic fatigue patients have breathing irregularities that may worsen their debilitating symptoms.
Two drug-free approaches — an elemental diet and VR-delivered CBT — showed meaningful IBS symptom relief in new clinical research.
Major fitness chain deploys cordless metabolic testing masks across all locations, offering lab-grade VO2 max assessments during workouts.
Tectonic Therapeutic enrolls 191 patients in a global trial of TX45, a novel fusion protein targeting a deadly heart-lung condition.
Biotin supplements taken by cancer patients for hair loss can distort key blood markers, potentially masking cancer recurrence or delaying treatment.
A phase III trial shows saroglitazar helped 57% of primary biliary cholangitis patients achieve biochemical response vs just 10% on placebo.
Engineered cardiac patches called BioVAT improved heart function and quality of life in early-stage heart failure patients.
Life Time's SpiroFit brings lab-grade VO₂ max and metabolic testing to everyday gym-goers, turning a key longevity biomarker into actionable fitness data.
Bepirovirsen, an antisense oligonucleotide, delivered functional cures in ~20% of chronic hepatitis B patients — a landmark leap over existing therapies.
Scientists found a brainstem area linked to forceful breathing also constricts blood vessels, offering new treatment targets.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
Stanford-Buck coalition develops intrinsic capacity score to quantify aging and test interventions through YMCA partnerships.
